复发/难治性 MCL 的治疗。
Treatment of Relapsed/Refractory MCL.
发表日期：2024 Jul 26
作者：
Elisabeth Silkenstedt, Martin Dreyling
来源：
BLOOD
摘要：
套细胞淋巴瘤是 B 细胞非霍奇金淋巴瘤的一种罕见亚型，其临床特征是其异质性行为，病程范围从惰性到高度侵袭性病例，预后有限。一线和复发环境中的靶向治疗替代方案越来越多地塑造 MCL 的治疗前景。新的靶向和免疫治疗方法的开发和实施已经改善了难治性或复发性疾病 MCL 患者的治疗结果。然而，长期预后仍然有限，患有复发/难治性疾病的患者，尤其是那些未能接受 BTK 抑制剂治疗的患者，通常结局不佳。本综述总结了当前和新兴的复发/难治性套细胞淋巴瘤的治疗方案，重点关注 BTK 抑制剂和 BCL2 抑制剂等联合靶向治疗策略以及 CART 细胞和双特异性抗体等免疫治疗方法的实施。版权所有 © 2024 年美国血液学会。
Mantle cell lymphoma is a rare subtype of B-cell Non-Hodgkin-lymphoma which is clinically characterized by its heterogeneous behaviour with courses ranging from indolent to highly aggressive cases with limited prognosis. Targeted treatment alternatives in first-line and relapse settings are more and more shaping the therapeutic landscape of MCL. The development and implementation of new targeted and immunotherapeutic approaches have already improved outcomes for MCL patients with refractory or relapsed disease. However, long-term prognosis is still limited and patients with relapsed/refractory disease, especially those failing BTK inhibitor treatment, usually have a dismal outcome. This review summarizes the current and emerging treatment options for relapsed/refractory mantle cell lymphoma, focusing on the implementation of combined targeted treatment strategies such as BTK inhibitors and BCL2 inhibitors as well as immune-therapeutic approaches including CART-cells and bispecific antibodies.Copyright © 2024 American Society of Hematology.